Cover Image

Vacuum-assisted breast biopsy after neoadjuvant systemic treatment for reliable exclusion of residual cancer in breast cancer patients

About 40 % of women with breast cancer achieve a pathologic complete response in the breast after neoadjuvant systemic treatment (NST). To identify these women, vacuum-assisted biopsy (VAB) was evaluated to facilitate risk-adaptive surgery. In confirmatory trials, the rates of missed residual cancer...

Full description

Saved in:
Bibliographic Details
Main Authors: Kölbel, Vivian (Author) , Pfob, André (Author) , Schäfgen, Benedikt (Author) , Sinn, Peter (Author) , Feißt, Manuel (Author) , Golatta, Michael (Author) , Gomez, Christina (Author) , Stieber, Anne (Author) , Bach, Paul (Author) , Rauch, Geraldine (Author) , Heil, Jörg (Author)
Format: Article (Journal)
Language:English
Published: 2022
In: Annals of surgical oncology
Year: 2022, Volume: 29, Issue: 2, Pages: 1076-1084
ISSN:1534-4681
DOI:10.1245/s10434-021-10847-9
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1245/s10434-021-10847-9
Get full text
Author Notes:Vivian Koelbel, André Pfob, Benedikt Schaefgen, Peter Sinn, Manuel Feisst, Michael Golatta, Christina Gomez, Anne Stieber, Paul Bach, Geraldine Rauch, Joerg Heil
Description
Summary:About 40 % of women with breast cancer achieve a pathologic complete response in the breast after neoadjuvant systemic treatment (NST). To identify these women, vacuum-assisted biopsy (VAB) was evaluated to facilitate risk-adaptive surgery. In confirmatory trials, the rates of missed residual cancer [false-negative rates (FNRs)] were unacceptably high (> 10%). This analysis aimed to improve the ability of VAB to exclude residual cancer in the breast reliably by identifying key characteristics of false-negative cases.
Item Description:Gesehen am 08.08.2023
Physical Description:Online Resource
ISSN:1534-4681
DOI:10.1245/s10434-021-10847-9

Similar Items